AorTech and SynCardia in artificial heart pact
This article was originally published in Clinica
SynCardia Systems is to use AorTech International’s Elast-Eon polymer heart valve in its temporary artificial heart technology after the two firms signed an exclusive licensing and supply agreement. According to Surbiton, UK-based AorTech, its valve has been shown to be more durable than biologic valves with comparable haemodynamic characteristics. SynCardia (Tucson, Arizona) will pay AorTech $2.1m over an 18-month period, with minimum valve purchases and volume-related discounts. The heart-assist device sector could reach a market value of $8-10bn within the coming decade, claims AorTech. SynCardia plans to submit the valve for CE mark and FDA approval in the second half of 2010.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals